Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICT-121 DC vaccine in recurrent glioblastoma
NCT02049489Phase 1Completed
- Sponsor
- Precision Lifesciences Group
- Start
- Dec 2013
- Primary completion
- Mar 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICT-121 DC vaccine in glioblastoma multiforme (GBM), sponsored by Precision Lifesciences Group. Primary endpoint: Safety and tolerability of an autologous ICT-121 DC vaccine. Started Dec 2013; status: completed.
02
Drugs
ICT-121 DC vaccine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02049489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049489.